UPDATED RESULTS FROM A PROSPECTIVE, RANDOMIZED PHASE 2 STUDY IN PATIENTS WITH FIRST RELAPSE OF HIGH-GRADE ASTROCYTOMA USING TVB-2640 IN COMBINATION WITH AVASTIN VERSUS AVASTIN ALONE

被引：0
|
作者：
Konkel, Brandon [1 ]
Caflisch, Laura [2 ]
Duque, Aldolfo Enrique Diaz [1 ]
Brenner, Andrew J. [1 ]
机构：
[1] UT Hlth San Antonio, Mays Canc Ctr, San Antonio, TX USA
[2] UT Hlth San Antonio, San Antonio, TX USA
来源：
NEURO-ONCOLOGY | 2018年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ACTR-25
引用
收藏
页码：16 / 16
页数：1
相关论文
共 49 条
  • [1] Prospective phase II trial in patients with first relapse of high-grade astrocytoma using TVB-2640 in combination with bevacizumab versus bevacizumab alone.
    Konkel, Brandon
    Caflisch, Laura D.
    Duque, Adolfo Enrique Diaz
    Michalek, Joel
    Liu, Qianqian
    Brenner, Andrew Jacob
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [2] Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
    Kelly, William
    Duque, Adolfo Enrique Diaz
    Michalek, Joel
    Konkel, Brandon
    Caflisch, Laura
    Chen, Yidong
    Pathuri, Sarath Chand
    Madhusudanannair-Kunnuparampil, Vinu
    Floyd II, John
    Brenner, Andrew
    CLINICAL CANCER RESEARCH, 2023, 29 (13) : 2419 - 2425
  • [3] A phase 2 study to determine the efficacy and safety of TVB-2640 in combination with bevacizumab in patients with first relapse of high grade astrocytoma.
    Duque, Adolfo Enrique Diaz
    De Feyter, Henk
    Kemble, George
    McCulloch, William
    Brenner, Andrew Jacob
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [4] Results of a Prospective Phase 2 Study of Pazopanib in Patients With Advanced Intermediate-Grade or High-Grade Liposarcoma
    Samuels, Brian L.
    Chawla, Sant P.
    Somaiah, Neeta
    Staddon, Arthur P.
    Skubitz, Keith M.
    Milhem, Mohammed M.
    Kaiser, Pamela E.
    Portnoy, David C.
    Priebat, Dennis A.
    Walker, Mark S.
    Stepanski, Edward J.
    CANCER, 2017, 123 (23) : 4640 - 4647
  • [5] Long-term survivors on SWOG 8737: A prospective, randomized, phase III trial of AZQ versus BCNU in high-grade astrocytoma patients
    Jaeckle, KA
    Rankin, C
    Townsend, JJ
    Eyre, HJ
    Knudson, HM
    Schulman, SF
    Hamilton, M
    Morantz, RA
    Vogel, FS
    Crowley, JJ
    NEUROLOGY, 2002, 58 (07) : A14 - A14
  • [6] Updated results of a phase 2 study of niraparib in heavily pretreated high-grade serous ovarian cancer patients in Japan
    Takehara, Kazuhiro
    Kondo, Eiji
    Yanagida, Satoshi
    Nakamura, Toshiaki
    Hamanishi, Junzou
    Harano, Kenichi
    Hasegawa, Kosei
    Hirasawa, Takeshi
    Hori, Kensuke
    Komiyama, Shinichi
    Matsuura, Motoki
    Nakai, Hidekatsu
    Nakamura, Hiroko
    Sakata, Jun
    Tabata, Tsutomu
    Takekuma, Munetaka
    Yokoyama, Yoshihito
    Kase, Yoichi
    Sugiyama, Toru
    Aoki, Daisuke
    ANNALS OF ONCOLOGY, 2021, 32 : S288 - S288
  • [7] NOVEL, FIRST-IN-CLASS, FATTY ACID SYNTHASE (FASN) INHIBITOR TVB-2640: EFFICACY, SAFETY AND BIOMARKER RESULTS FROM A GLOBAL PHASE 2 RANDOMIZED PBO-CONTROLLED NASH TRIAL, FASCINATE-1
    Harrison, Stephen
    Grimmer, Katharine
    Martins, Eduardo B.
    OFarrell, Marie
    Kemble, George
    Loomba, Rohit
    GASTROENTEROLOGY, 2022, 162 (07) : S1273 - S1274
  • [8] First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study
    Bergh, Jonas
    Bondarenko, Igor M.
    Lichinitser, Mikhail R.
    Liljegren, Annelie
    Greil, Richard
    Voytko, Nataliya L.
    Makhson, Anatoly N.
    Cortes, Javier
    Lortholary, Alain
    Bischoff, Joachim
    Chan, Arlene
    Delaloge, Suzette
    Huang, Xin
    Kern, Kenneth A.
    Giorgetti, Carla
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (09) : 921 - 929
  • [9] Adjuvant lenvatinib in combination with TACE for hepatocellular carcinoma patients with high risk of postoperative relapse (LANCE): Updated results from a multi-center prospective cohort study
    Chen, J.
    Lu, L.
    Wen, T-F.
    Lu, C-D.
    Zeng, Y-Y.
    Xiang, B-D.
    Xu, X.
    Huang, Z-Y.
    Li, X-C.
    Zhang, T.
    Qin, L-X.
    ANNALS OF ONCOLOGY, 2021, 32 : S824 - S825
  • [10] An Open-label Randomized Phase 2 study of Durvalumab Alone or in Combination with Tremelimumab in Patients with Advanced Germ Cell Tumors (APACHE): Results from the First Planned Interim Analysis
    Necchi, Andrea
    Giannatempo, Patrizia
    Raggi, Daniele
    Mariani, Luigi
    Colecchia, Maurizio
    Fare, Elena
    Monopoli, Francesco
    Calareso, Giuseppina
    Ali, Siraj M.
    Ross, Jeffrey S.
    Chung, Jon H.
    Salvioni, Roberto
    EUROPEAN UROLOGY, 2019, 75 (01) : 201 - 203
12345